...A. That will, of course, by the end of 2025 be $1 billion in gross savings, [$800 million] in net. B. We have litifilimab, obviously BIIB080 another molecule that we call our crown jewel. C. So for example, we still invest in VUMERITY, which is our number one, it's the number one branded oral. D. And I can say even from sitting in my seat, it was literally my, 100% of my savings went into 100% of my launches, which was for LEQEMBI, SKYCLARYS , which I know we'll talk about today. E. We had the acquisition of Reata, which SKYCLARYS was really a beautiful fit into our portfolio....